Screener
Lexicon Pharmaceuticals LXRX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 |
| Loss on early extinguishment of debt | (4,349) | — | (4,349) | — |
| Net (loss) income | $(31,775) | $3,252 | $(32,818) | $(22,043) |
| Net (loss) income per common share, basic | $(0.07) | $0.01 | $(0.08) | $(0.06) |
| Net (loss) income per common share, diluted | $(0.07) | $0.01 | $(0.08) | $(0.06) |
| Weighted average common shares outstanding, basic | 437,653 | 363,294 | 419,050 | 362,687 |
| Weighted average common shares outstanding, diluted | 437,653 | 363,570 | 419,050 | 362,687 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — net loss?
- Lexicon Pharmaceuticals (LXRX) reported business segments — net loss of -$31.78M in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — net loss changed year-over-year?
- Lexicon Pharmaceuticals's business segments — net loss decreased by 1077.1% year-over-year, from $3.25M to -$31.78M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — net loss?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — net loss has grown at a -21.0% compound annual growth rate (CAGR), from -$101.94M to -$50.34M.
- What does business segments — net loss mean?
- This metric measures the bottom-line financial performance of a specific business segment after accounting for all associated revenues, operating expenses, and non-operating costs. It indicates the extent to which a segment is currently consuming capital rather than generating profit, which is common in research-intensive biopharmaceutical development phases. A reduction in this loss over time is a key indicator of improved operational efficiency or successful commercialization progress.
Ask your AI about Lexicon Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude